Anticoagulation in portal vein thrombosis among patients with cirrhosis; myths vs evidence (ondemand)-Anticoagulation

Video Transcription

Video Summary

This webinar reviewed anticoagulation for portal vein thrombosis (PVT) in patients with cirrhosis, focusing on practical decisions beyond current guidelines.<br /><br />Dr. Jessica Davis opened with a case-based approach. She emphasized that many PVTs resolve spontaneously, but extensive, acute, occlusive PVT—especially in transplant candidates—often merits anticoagulation. She discussed outcomes showing that PVT can complicate liver transplant and that anticoagulation may improve recanalization, reduce decompensation, and possibly improve survival, with benefits that may extend beyond clot resolution. She compared treatment options: DOACs, warfarin, and low molecular weight heparin, noting the pros and cons of each in cirrhosis. She also addressed duration of therapy, suggesting at least six months after recanalization and often longer, especially in transplant candidates. For persistent clot despite anticoagulation, she highlighted TIPS as an option, particularly when there are other indications such as refractory ascites or variceal bleeding.<br /><br />Dr. Marco Senzolo focused on bleeding risk assessment. He argued that anticoagulation does not substantially increase bleeding risk in cirrhosis and may even lower portal hypertensive bleeding by improving portal flow and recanalizing the vein. He stressed that INR is not a reliable predictor of bleeding risk and that platelet count alone is also a poor guide. Instead, bleeding risk should be assessed based on overall liver disease severity, renal dysfunction, infection, and procedure-related risks. He noted that portal hypertensive bleeding is driven more by the PVT and portal hypertension than by anticoagulation itself.<br /><br />In Q&A, both speakers agreed that anticoagulation is often restarted quickly after procedures and that practice remains variable, especially for paracentesis and endoscopic band ligation.

Keywords

portal vein thrombosis

cirrhosis

anticoagulation

liver transplant

recanalization

direct oral anticoagulants

warfarin

low molecular weight heparin

TIPS

bleeding risk assessment